cardiovascular

Heart Rate Variability and Blood Sugar: What Your HRV Is Telling You About Your Diabetes

by

Heart rate variability — the variation in time between consecutive heartbeats — has emerged as one of the most informative biomarkers in modern medicine. For people with diabetes, HRV is particularly significant: it reflects the health of the autonomic nervous system, predicts cardiovascular risk, and responds measurably to blood sugar changes. With wearable technology now making HRV accessible to everyone, understanding what it means has never been more important.

What Is Heart Rate Variability?

Despite what the name might suggest, a healthy heart does not beat with metronomic regularity. The interval between beats varies constantly — influenced by breathing, physical activity, stress, and the balance between the sympathetic (fight-or-flight) and parasympathetic (rest-and-digest) branches of the autonomic nervous system. This variability is HRV, and higher variability generally reflects a healthier, more adaptable autonomic nervous system.

Low HRV indicates that the autonomic nervous system is under stress or has reduced adaptability — a state associated with cardiovascular disease, inflammation, poor recovery from exercise, and in the context of diabetes, cardiac autonomic neuropathy (CAN).

HRV and Diabetes: The Cardiac Autonomic Neuropathy Connection

Cardiac autonomic neuropathy is a serious but underdiagnosed complication of diabetes, affecting approximately 20% of people with type 1 diabetes and up to 30% of people with type 2 diabetes. It results from damage to the autonomic nerve fibres that regulate heart rate and vascular tone, caused by chronic hyperglycaemia and oxidative stress.

CAN manifests as reduced HRV, resting tachycardia, orthostatic hypotension (dizziness on standing), and exercise intolerance. In its advanced stages, it is associated with a 3–5 fold increase in cardiovascular mortality and is a recognised cause of sudden cardiac death in diabetes.

How Blood Sugar Affects HRV in Real Time

Research using simultaneous CGM and HRV monitoring has revealed a direct, real-time relationship between glucose levels and autonomic function. Both hyperglycaemia (high blood sugar) and hypoglycaemia (low blood sugar) acutely reduce HRV. Post-meal glucose spikes trigger sympathetic nervous system activation, reducing parasympathetic tone and lowering HRV. Nocturnal hypoglycaemia causes profound HRV suppression and is associated with cardiac arrhythmias during sleep.

How to Improve Your HRV with Diabetes

✅ Evidence-Based Strategies to Improve HRV
  • Optimise blood sugar control — reducing glucose variability is the most direct way to improve HRV in diabetes
  • Regular aerobic exercise — 150 minutes per week of moderate-intensity exercise significantly improves HRV
  • Diaphragmatic breathing — slow, deep breathing at 6 breaths/minute acutely increases HRV
  • Sleep quality — HRV is predominantly restored during deep sleep; prioritise 7–9 hours
  • Stress management — chronic psychological stress is a major driver of low HRV
  • Avoid alcohol — even moderate alcohol consumption suppresses HRV for 24–48 hours
💡 Key Takeaway

HRV is a window into your autonomic nervous system health — and in diabetes, it is a sensitive early marker of cardiac autonomic neuropathy and cardiovascular risk. If your wearable device shows consistently low HRV, discuss it with your diabetes team. Improving blood sugar control, exercising regularly, sleeping well, and managing stress are all proven ways to improve HRV and protect your heart.

Related articles

Quit Smoking with Diabetes: Why It Matters More Than You Think

by

Smoking is the single most preventable cause of death in the world. For people with diabetes, it is even more dangerous — it dramatically amplifies every cardiovascular, renal, and neuropathic complication that diabetes already causes. If you smoke and have diabetes, quitting is the single most impactful health decision you can make.

How Smoking Worsens Diabetes

The interaction between smoking and diabetes is profoundly harmful. Nicotine and other tobacco chemicals worsen insulin resistance, making blood sugar harder to control. Smoking causes endothelial dysfunction — damage to the inner lining of blood vessels — which accelerates atherosclerosis. It raises LDL cholesterol and triglycerides while lowering protective HDL cholesterol. It promotes inflammation and oxidative stress, both of which are already elevated in diabetes.

The result is a multiplicative — not merely additive — increase in cardiovascular risk. A person with diabetes who smokes has 3–4 times the cardiovascular risk of a non-smoking person with diabetes.

What Happens When You Quit

✅ Timeline of Benefits After Quitting

  • 20 minutes: Heart rate and blood pressure drop
  • 12 hours: Carbon monoxide levels in blood normalise
  • 2–12 weeks: Circulation improves; insulin sensitivity begins to improve
  • 1 year: Risk of coronary heart disease halved compared to a smoker
  • 5 years: Stroke risk reduced to that of a non-smoker
  • 10 years: Lung cancer risk halved; risk of other cancers decreases

Effective Quitting Methods

Method Success Rate at 12 months Notes
Varenicline (Champix) ~25–30% Most effective pharmacotherapy; prescription required
NRT + Behavioural Support ~20–25% Patches, gum, lozenges; available OTC
Bupropion ~15–20% Antidepressant with smoking cessation effect
Willpower alone ~3–5% Least effective; combine with support for best results
💡 Key Takeaway

If you have diabetes and you smoke, quitting is the single most powerful action you can take to protect your health. The combination of smoking and diabetes creates a cardiovascular risk that is far greater than the sum of its parts. Use evidence-based methods — varenicline or NRT combined with behavioural support — and ask your GP or diabetes team for help. You do not have to do this alone.

Tirzepatide and Cardiovascular Outcomes: What the SURMOUNT and SURPASS Trials Tell Us

by

Tirzepatide (Mounjaro) has rapidly become one of the most discussed medications in diabetes and obesity medicine. Its dual GIP/GLP-1 receptor agonist mechanism produces unprecedented reductions in blood sugar and body weight. But what does the evidence say about its cardiovascular effects — and how does it compare to semaglutide?

How Tirzepatide Works

Unlike semaglutide, which acts on GLP-1 receptors alone, tirzepatide is a dual agonist — it activates both GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously. This dual mechanism produces synergistic effects on insulin secretion, glucagon suppression, gastric emptying, and appetite regulation, resulting in greater weight loss and blood sugar reduction than GLP-1 agonists alone.

The SURPASS Trial Programme: Blood Sugar and Weight Results

The SURPASS clinical trial programme, which evaluated tirzepatide across more than 6,000 participants with type 2 diabetes, produced remarkable results. At the highest dose (15mg weekly), tirzepatide reduced HbA1c by an average of 2.58% — the largest reduction ever seen with any glucose-lowering medication in a phase 3 trial. Body weight reductions of 11–15 kg were observed across the programme.

Cardiovascular Risk Factor Improvements

Risk FactorChange with Tirzepatide 15mg
Body weight↓ 11–15 kg (up to 22% in obesity trials)
Systolic blood pressure↓ 7–10 mmHg
Triglycerides↓ 24–28%
HDL cholesterol↑ 6–10%
Waist circumference↓ 10–14 cm

The SURPASS-CVOT Trial: Definitive Cardiovascular Evidence

The dedicated cardiovascular outcomes trial for tirzepatide — SURPASS-CVOT — has been designed to determine whether tirzepatide reduces major adverse cardiovascular events (MACE: heart attack, stroke, cardiovascular death) in people with type 2 diabetes and established cardiovascular disease. Results are anticipated in 2025–2026 and are expected to confirm cardiovascular benefit based on the surrogate marker improvements already observed.

💡 Key Takeaway

Tirzepatide produces the most impressive improvements in cardiovascular risk factors of any glucose-lowering medication to date — including dramatic reductions in weight, blood pressure, and triglycerides. While definitive cardiovascular outcomes data is pending, the evidence strongly suggests it will join semaglutide as a cardioprotective medication. If you have type 2 diabetes and significant cardiovascular risk, discuss tirzepatide with your diabetes team.

Related articles

When Should Someone with Diabetes See a Cardiologist?

by

Diabetes significantly increases cardiovascular risk, yet many people with diabetes never see a cardiologist — even when they should. Knowing when to ask for a cardiology referral, and what to expect when you get one, could be one of the most important steps you take for your long-term health.

Why People with Diabetes Have Elevated Cardiovascular Risk

Cardiovascular disease is the leading cause of death in people with both type 1 and type 2 diabetes. The mechanisms are multiple and interconnected: chronic hyperglycaemia damages blood vessel walls; insulin resistance promotes dyslipidaemia and hypertension; advanced glycation end-products (AGEs) stiffen arterial walls; and chronic inflammation accelerates atherosclerotic plaque formation. The result is that people with diabetes develop cardiovascular disease earlier, more severely, and with less warning than people without diabetes.

Signs You Should Ask for a Cardiology Referral

🚨 Seek Urgent Medical Attention Immediately If You Have:

  • Chest pain, tightness, pressure, or discomfort — especially with exertion
  • Shortness of breath at rest or with minimal activity
  • Palpitations, irregular heartbeat, or episodes of rapid heart rate
  • Unexplained dizziness, fainting, or near-fainting episodes
  • Swelling of the legs or ankles (possible heart failure)
  • Sudden severe fatigue or unexplained exercise intolerance

When to Request a Routine Cardiology Referral

Beyond emergency symptoms, there are several situations where a planned cardiology referral is appropriate for people with diabetes:

  • Diabetes duration of 10+ years with additional risk factors (hypertension, dyslipidaemia, smoking, obesity, family history)
  • Abnormal ECG findings at your annual diabetes review
  • Established chronic kidney disease (eGFR <60) — strongly associated with cardiovascular risk
  • History of peripheral arterial disease (poor circulation in legs)
  • Multiple failed attempts to reach blood pressure or cholesterol targets despite medication
  • Considering high-intensity exercise after a period of inactivity

What Happens at a Cardiology Appointment?

A cardiology assessment for someone with diabetes typically includes a detailed history and physical examination, resting ECG, echocardiogram (ultrasound of the heart), exercise stress test (if appropriate), and blood tests including BNP (a marker of heart strain). Depending on findings, further investigations such as coronary CT angiography or nuclear stress testing may be arranged.

💡 Key Takeaway

Do not wait for symptoms to ask about your heart health. If you have had diabetes for more than 10 years, have additional cardiovascular risk factors, or have any of the warning signs listed above, speak to your GP about a cardiology referral. Early detection and intervention saves lives — and in diabetes, the cardiovascular clock starts ticking at diagnosis.

Statins and Diabetes: Understanding the Risks, Benefits, and the Latest Evidence

by

Statins are among the most prescribed medications in the world, and for people with diabetes, they are a cornerstone of cardiovascular risk reduction. Yet they are also among the most misunderstood — surrounded by myths about muscle damage, memory loss, and a supposed link to worsening diabetes. This guide cuts through the noise with evidence-based clarity.

Why People with Diabetes Are Recommended Statins

Diabetes is an independent cardiovascular risk factor. People with type 2 diabetes have a 2–4 times higher risk of heart attack and stroke compared to people without diabetes. This elevated risk is driven by the combination of insulin resistance, dyslipidaemia (high triglycerides, low HDL, small dense LDL particles), hypertension, and chronic low-grade inflammation.

Statins work by inhibiting HMG-CoA reductase, the enzyme responsible for cholesterol synthesis in the liver. This reduces LDL cholesterol (the primary driver of atherosclerotic plaque formation) and has additional pleiotropic effects including anti-inflammatory and plaque-stabilising properties.

The Evidence: How Much Do Statins Reduce Cardiovascular Risk?

The evidence for statins in people with diabetes is compelling. The Cholesterol Treatment Trialists’ Collaboration meta-analysis of over 170,000 participants found that each 1 mmol/L reduction in LDL cholesterol with statin therapy reduces major cardiovascular events by approximately 21%. In people with diabetes, the absolute risk reduction is even greater because their baseline risk is higher.

Do Statins Cause Diabetes?

This is the most frequently asked question about statins in people who already have diabetes. The answer is nuanced. Statin therapy is associated with a modest increase in the risk of new-onset type 2 diabetes in people who do not yet have the condition — approximately a 10–12% relative increase in risk. However, this must be weighed against the substantial cardiovascular benefit.

⚠️ Important Clarification

For people who already have diabetes, statins do not meaningfully worsen blood sugar control. The modest increase in HbA1c (approximately 0.1–0.3%) seen in some studies is clinically insignificant compared to the substantial cardiovascular protection they provide. Do not stop your statin without discussing it with your doctor.

Statin Comparison: Which One Is Right for You?

StatinIntensityLDL ReductionNotes
Rosuvastatin 20–40mgHigh50–60%Preferred for high CVD risk; once daily
Atorvastatin 40–80mgHigh45–55%Most widely prescribed; once daily
Simvastatin 20–40mgModerate35–45%More drug interactions; evening dosing
Pravastatin 40mgModerate30–40%Fewer drug interactions; good for elderly
💡 Key Takeaway

For most people with diabetes aged over 40, or with any additional cardiovascular risk factor, statin therapy is recommended by all major guidelines. The cardiovascular benefits substantially outweigh the risks. If you experience muscle aches or other side effects, speak to your doctor — switching to a different statin or adjusting the dose often resolves the problem. Never stop your statin without medical advice.

Related articles

Walking for Heart Health with Diabetes: A 4-Week Programme

by

Walking is the most accessible, evidence-based exercise for people with diabetes. It requires no equipment, no gym membership, and no special fitness level. Yet its cardiovascular and metabolic benefits are profound: regular brisk walking reduces HbA1c, lowers blood pressure, improves cholesterol, aids weight management, and reduces the risk of major cardiovascular events by up to 30%.

The Evidence for Walking in Diabetes

A landmark meta-analysis published in Diabetes Care found that walking programmes reduced HbA1c by an average of 0.5% in people with type 2 diabetes — comparable to the effect of some oral medications. The NAVIGATOR trial and multiple prospective cohort studies have shown that walking 30 minutes per day, five days per week, reduces the risk of cardiovascular events by 19–30% in people with diabetes.

Post-meal walking is particularly effective for blood glucose management. Research shows that a 10–15 minute walk after meals reduces post-prandial glucose spikes by 12–22% — more effectively than a single 30-minute walk at another time of day. This makes post-meal walking one of the simplest and most impactful interventions available.

Your 4-Week Heart Health Walking Programme

WeekDurationFrequencyIntensityFocus
Week 115–20 min4× per weekComfortable paceBuild habit; check glucose response
Week 220–25 min4–5× per weekBrisk (slightly breathless)Increase pace; add post-meal walks
Week 325–30 min5× per weekBrisk with 2-min faster intervalsIntroduce interval walking
Week 430 min5× per weekBrisk with 5-min faster intervalsConsolidate routine; aim for 150 min/week
⚠️ Safety Tips for Walking with Diabetes
  • Check blood glucose before walking if on insulin or sulfonylureas; aim for 7–10 mmol/L
  • Carry fast-acting glucose (glucose tablets or gel) on every walk
  • Wear well-fitting, cushioned footwear and check feet after each walk
  • Avoid walking in extreme heat or cold, which can affect glucose and cardiovascular stress
  • Wear a medical ID or carry identification noting your diabetes
💡 Key Takeaway

Walking is one of the most powerful and accessible interventions for cardiovascular health in diabetes. Even 10-minute post-meal walks can meaningfully reduce glucose spikes. This 4-week programme provides a structured, progressive approach to building a sustainable walking habit that protects both your heart and your blood sugar.

Related articles

Alcohol and Heart Health with Diabetes: What You Need to Know

by

Alcohol and diabetes have a complicated relationship. Moderate consumption may offer some cardiovascular benefits, yet alcohol can cause dangerous hypoglycaemia, interact with diabetes medications, and contribute to weight gain and elevated triglycerides. Understanding the risks and making informed choices is essential for anyone managing diabetes who chooses to drink.

How Alcohol Affects Blood Glucose

The liver plays a central role in both alcohol metabolism and blood glucose regulation. When alcohol is consumed, the liver prioritises metabolising ethanol over its normal glucose-producing functions (gluconeogenesis and glycogenolysis). This means that for several hours after drinking, the liver’s ability to release glucose into the bloodstream is impaired — creating a significant risk of hypoglycaemia, particularly in people taking insulin or sulfonylureas.

This risk is compounded by the fact that hypoglycaemia symptoms (confusion, dizziness, slurred speech) can easily be mistaken for intoxication — both by the person themselves and by bystanders. This is why wearing a medical ID and informing companions about diabetes is particularly important when drinking.

⚠️ Alcohol and Hypoglycaemia Risk
  • Hypoglycaemia can occur up to 12–24 hours after drinking
  • Never drink on an empty stomach — always eat carbohydrates with alcohol
  • Check blood glucose before bed after drinking; have a carbohydrate snack if below 7 mmol/L
  • Set an alarm to check glucose during the night if you have consumed significant alcohol
  • Glucagon may be less effective when alcohol is present — ensure companions know this

Cardiovascular Effects: The Evidence

The relationship between alcohol and cardiovascular health has been extensively debated. Observational studies have suggested a J-shaped curve: moderate drinkers (1–2 units per day) appear to have lower rates of coronary heart disease than non-drinkers, potentially due to alcohol’s effects on HDL cholesterol and platelet aggregation. However, more recent Mendelian randomisation studies — which are less susceptible to confounding — suggest that even moderate alcohol consumption increases overall cardiovascular risk, particularly for atrial fibrillation, hypertension, and haemorrhagic stroke.

The current consensus from major cardiovascular organisations is that there is no safe level of alcohol consumption from a purely cardiovascular perspective. If you do not currently drink, there is no cardiovascular justification to start.

Practical Guidelines for Drinking with Diabetes

GuidelineRecommendation
Maximum intakeNo more than 14 units per week (UK); spread over 3+ days
Best choicesDry wine, spirits (with sugar-free mixers); avoid sugary cocktails and beer
Always eatNever drink on an empty stomach; eat carbohydrates with alcohol
Monitor glucoseCheck before, during (if prolonged), and before bed; set overnight alarm
Wear medical IDEnsures correct treatment if hypo is mistaken for intoxication
💡 Key Takeaway

Alcohol can be consumed in moderation by most people with diabetes, but it requires careful management. The primary risks are hypoglycaemia (particularly delayed, overnight hypos) and elevated triglycerides. Always eat when drinking, monitor glucose carefully, and keep within recommended limits. If you take insulin or sulfonylureas, discuss alcohol management specifically with your diabetes team.

Related articles

SGLT2 Inhibitors: Heart and Kidney Protection Beyond Blood Sugar

by

SGLT2 inhibitors represent one of the most transformative developments in diabetes medicine in the past decade. Originally approved as glucose-lowering agents, these medications have since demonstrated remarkable protective effects on the heart and kidneys — benefits so significant that they are now recommended for people with heart failure and chronic kidney disease even in the absence of diabetes.

How SGLT2 Inhibitors Work

Sodium-glucose cotransporter-2 (SGLT2) inhibitors work by blocking the SGLT2 protein in the kidney’s proximal tubule, which is responsible for reabsorbing approximately 90% of filtered glucose back into the bloodstream. By inhibiting this transporter, SGLT2 inhibitors cause the kidneys to excrete excess glucose in the urine — effectively lowering blood sugar without stimulating insulin secretion.

This mechanism also produces several secondary effects: a modest reduction in blood pressure (through osmotic diuresis and natriuresis), weight loss (due to caloric loss through glycosuria), and a reduction in intraglomerular pressure (which protects the kidneys from hyperfiltration damage).

The Landmark Cardiovascular and Renal Outcome Trials

TrialDrugKey Finding
EMPA-REG OUTCOME (2015)Empagliflozin38% reduction in CV death; 35% reduction in heart failure hospitalisation
CANVAS (2017)Canagliflozin14% reduction in MACE; significant reduction in heart failure hospitalisation
DAPA-HF (2019)Dapagliflozin26% reduction in worsening heart failure or CV death — in patients with and without diabetes
CREDENCE (2019)Canagliflozin30% reduction in kidney failure, dialysis, or renal death in diabetic kidney disease
⚠️ Important Side Effects to Know
  • Genital mycotic infections: The most common side effect (increased glucose in urine promotes yeast growth). Good genital hygiene and prompt treatment if symptoms develop
  • Diabetic ketoacidosis (DKA): Rare but serious, even with near-normal glucose levels. Sick day rules are essential — hold the medication during illness, surgery, or prolonged fasting
  • Urinary tract infections: Slightly increased risk; stay well hydrated
  • Volume depletion: Can cause dizziness, especially in elderly patients or those on diuretics

Who Should Consider an SGLT2 Inhibitor?

Current ADA and ESC guidelines recommend SGLT2 inhibitors with proven cardiovascular benefit as a preferred add-on therapy for people with type 2 diabetes who have established cardiovascular disease, heart failure, or chronic kidney disease — independent of HbA1c. They are now also approved for heart failure and chronic kidney disease in patients without diabetes.

💡 Key Takeaway

SGLT2 inhibitors are no longer just glucose-lowering drugs — they are cardioprotective and nephroprotective agents with a robust evidence base. If you have type 2 diabetes with heart disease, heart failure, or kidney disease, speak with your doctor about whether an SGLT2 inhibitor is appropriate for you.

Related articles

Omega-3 Fatty Acids and Diabetes: Do Supplements Actually Help?

by

Omega-3 fatty acids are among the most extensively studied dietary supplements in cardiovascular medicine. For people with diabetes — who face elevated triglycerides, increased cardiovascular risk, and chronic inflammation — the question of whether omega-3 supplements provide meaningful benefit is both clinically important and surprisingly nuanced.

What Are Omega-3 Fatty Acids?

Omega-3 fatty acids are a family of polyunsaturated fats. The three most clinically relevant forms are eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA). EPA and DHA are found primarily in fatty fish (salmon, mackerel, sardines, herring) and in fish oil supplements. ALA is found in plant sources such as flaxseed, chia seeds, and walnuts, but is only partially converted to EPA and DHA in the body — making marine sources far more bioavailable.

What Does the Evidence Show?

Triglyceride reduction: This is the most consistently demonstrated benefit of omega-3 supplementation. High-dose EPA+DHA (2–4 grams per day) reduces triglycerides by 15–30%. This is clinically significant for people with diabetes, who commonly have elevated triglycerides as part of diabetic dyslipidaemia.

Cardiovascular outcomes: The evidence here is more mixed. The REDUCE-IT trial (2018) showed that high-dose icosapentaenoic acid (EPA only, as icosapentaenoic acid ethyl ester — Vascepa) at 4 grams per day reduced major cardiovascular events by 25% in high-risk patients with elevated triglycerides. However, the STRENGTH and ORIGIN trials, using standard fish oil at lower doses, showed no cardiovascular benefit.

Blood glucose: Standard-dose omega-3 supplements do not significantly affect HbA1c or fasting glucose in people with type 2 diabetes. Some early concerns about high-dose fish oil raising blood glucose have not been confirmed in well-controlled trials.

Inflammation: EPA and DHA reduce levels of inflammatory markers including C-reactive protein, interleukin-6, and tumour necrosis factor-alpha. Given that chronic inflammation drives both insulin resistance and cardiovascular disease, this anti-inflammatory effect is clinically relevant even if its direct impact on outcomes is difficult to isolate.

⚠️ Food First: The Case for Dietary Omega-3s

The strongest evidence for omega-3 benefits comes from dietary intake of fatty fish, not supplements. The PREDIMED trial demonstrated that a Mediterranean diet rich in fish and olive oil reduced cardiovascular events by 30% — an effect attributable to the whole dietary pattern, not any single nutrient. Aim for 2–3 servings of fatty fish per week before reaching for a supplement.

Who Should Consider Omega-3 Supplements?

Based on current evidence, omega-3 supplementation is most justified in the following scenarios: triglycerides persistently above 500 mg/dL (where high-dose omega-3s are an established treatment for pancreatitis prevention); triglycerides between 150–499 mg/dL in high cardiovascular risk patients (where high-dose EPA-only preparations like icosapentaenoic acid may be considered); and individuals who cannot or do not eat fatty fish regularly.

✅ Practical Omega-3 Recommendations

  • Aim for 2–3 servings of fatty fish per week (salmon, mackerel, sardines)
  • If supplementing, choose a product providing at least 1g combined EPA+DHA per day
  • For triglyceride reduction, doses of 2–4g EPA+DHA per day are needed
  • Look for supplements with third-party purity certification (IFOS or similar)
  • Always discuss supplementation with your doctor, especially if on blood thinners
💡 Key Takeaway

Omega-3 fatty acids offer genuine benefits for triglyceride reduction and inflammation in people with diabetes. However, dietary sources (fatty fish) remain superior to supplements for overall cardiovascular protection. High-dose EPA-only preparations may be appropriate for high-risk patients with persistently elevated triglycerides — discuss this with your care team.